stock-detail (OGXI)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

Inherited Mutation Doubles The Risk Of Death From Malignant Melanoma

6/15/2016 11:05 am

(Karolinska Institutet [Stockholm, Sweden]) June 13, 2016 - People with malignant melanoma with an inherited mutation in a certain gene are twice as likely to die of the disease, according to a new study.

Kaiser Permanente Study Finds Breast Cancer Patients Taking Newer Hormone Therapy Drugs Have No Increased Risk of Fatal Cardiovascular Events

4/22/2016 11:01 am

(Kaiser Permanente) Apr 21, 2016 - In a new study, researchers found the use of aromatase inhibitors was not associated with an increased risk of fatal cardiovascular events compared with tamoxifen.

Young Adult Survivors Of Childhood Cancer Report Overall Health Similar To Middle-Aged In General Population

4/22/2016 11:01 am

(Harvard T.H. Chan School of Public Health) Apr 21 2016 - According to new research from Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard T.H. Chan School of Public Health, overall health-related quality of life in young adult survivors of childhood cancer resembles that of middle-aged adults.

Minority of Cancer Cells Affect The Growth And Metastasis Of Tumors

2/3/2016 11:04 am

(Lund University [Sweden]) Feb 2, 2016 - New research shows that a small minority of cancer cells in neuroendocrine tumours of the pancreas contribute to the overall growth and metastasis of the tumour. This discovery was made by a research group at Lund University, in collaboration with researchers at Karolinska Institutet, in Sweden.

Mallinckrodt Buys Immunotherapy Maker Therakos For $1.33 Billion

8/10/2015 11:05 am

(Reuters) Aug 10, 2015 - Dublin-based drugmaker Mallinckrodt Plc said it would buy immunotherapy company Therakos Inc in a deal valued at about $1.33 billion, its second major acquisition this year aimed at strengthening its hospital offerings.

Cancer Genetics of Rutherford Agrees To Buy Los Angeles-Based Company

8/10/2015 11:05 am

( Record) Aug 10, 2015 - Cancer Genetics Inc. said Monday it agreed to buy Los Angeles-based Response Genetics Inc. for $14 million, adding expertise in solid tumor molecular diagnosis.

Mediterranean Diet Reduces Risk of Womb Cancer, Study

5/27/2015 11:05 am

(French Tribune) May 27, 2015 - According to a new study, adapting a Mediterranean diet can significantly reduce to risk of getting womb cancer. The researchers found that those who followed a Mediterranean diet have lowered their risk of womb cancer by 57 per cent.

Clinical Trial Reduces Stress of Cancer Caregivers

5/27/2015 11:05 am

(UCCC/In the Clinic blog) May 26, 2015 - Cancer caregivers are stressed, potentially impacting the quality of the care they give. A CU Cancer Center clinical trial demonstrates how to help.

AstraZeneca-Novartis Three-Drug Melanoma Treatment Found Safe

5/14/2015 12:05 pm

(Bloomberg) May 13, 2015 - A first-of-its-kind combination of three drugs to treat a deadly form of skin cancer can be taken safely, passing the first hurdle to regulatory approval for a potentially long-lasting treatment.

FDA Kicks off Generic Drug User Fee Reauthorization Process

4/22/2015 12:00 pm

(RAPS/Regulatory Focus) Apr 21, 2015 - Regulators and generic pharmaceutical companies, start your engines. The race to the next reauthorization of the Generic Drug User Fee Act (GDUFA) has begun.

Genetic Test Could Help Identify Breast Cancer Risk

4/9/2015 11:04 am

(Cancer Research UK/Press Association) Apr 9, 2015 - UK researchers have taken a step towards identifying women at increased risk of breast cancer by analysing their DNA.

New Waldenström’s Drug Shows Sustained Benefit at Two Years

4/9/2015 11:04 am

(Dana-Farber) Apr 8, 2015 - The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenström’s Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute.

Biggest U.S. Health Insurer Tightens Rules on Hysterectomy Coverage

2/27/2015 11:05 am

(Wall Street Journal) Feb 26, 2015 - UnitedHealth to require doctors to get authorization before performing most types of procedures; decision marks another blow to laparoscopic power morcellator, which can spread hidden cancer.

Allegheny Health Network Physician Research Points to Possible New Paradigm in Ovarian Cancer Treatment

2/11/2015 11:05 am

(Allegheny Health Network) Feb 10, 2015 - Aggressive surgery to remove all visible disease in ovarian cancer patients may have little benefit for some patients whose cancer is highly advanced at diagnosis, according to a study published in today’s Journal of Clinical Oncology.

A Never-Ending Genetic Quest

2/10/2015 11:05 am

(New York Times) Feb 9, 2015 - Mary-Claire King discovered BRCA1, the so-called breast cancer gene, and now believes every woman should be tested. A condensed and edited version of an interview with Dr. King follows.

ASCO: 'High-Risk' Project 'Must Be Done'

1/22/2015 11:03 am

(Medscape Medical News) Jan 22, 2015 - The organization has been claiming that CancerLinQ will revolutionize cancer care for months. Now they have a technology partner to help them.

Celgene, Biotech's Ace Dealmaker, Bets on Canada's Zymeworks

1/22/2015 11:03 am

(Forbes) Jan 21, 2015 - Celgene, the big maker of blood cancer drugs, has gained a reputation for anointing biotech startups before they break out. Now it’s betting on a little Canadian biotech, Zymeworks, with technology for engineering new types of targeted antibody drugs.

Puma Forced to Delay Breast Cancer FDA Submission Due to New Safety Data Requirement

12/3/2014 11:05 am

(TheStreet) Dec 2, 2014 - Puma Biotechnology is pushing back an approval filing for its breast cancer drug neratinib into 2016 -- almost a one year delay.

Exelixis Announces Positive Preliminary Data From an Investigator-Sponsored Phase 1 Trial of XL888 and Vemurafenib

11/17/2014 05:01 am

(Yahoo! Finance) Nov 16, 2014 - Exelixis, Inc. today announced preliminary results from a phase 1 investigator-sponsored trial (IST) evaluating the safety and activity of XL888, an Exelixis-discovered small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), in combination with vemurafenib in patients with unresectable stage III/IV BRAF V600 mutation-positive melanoma.

Researchers Find New Target for Kidney Cancer Therapy

11/11/2014 06:00 am

(UC Academic Health Center) Nov 10, 2014 - Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease, which currently has few treatment options.

FDA Approves Ramucirumab For Advanced Gastric or GE Junction Adenocarcinoma

11/6/2014 06:01 am

(ASCO in Action) Nov 5, 2014 - On November 5, 2014, the U. S. Food and Drug Administration approved ramucirumab (Cyramza®, Eli Lilly and Company) for use in combination with paclitaxel for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

11/4/2014 06:01 am

(Reuters) Nov 4, 2014 - Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial.

Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer

11/4/2014 02:05 am

(Amgen) Nov 4, 2014 - Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival.

Hacker Breached Insurance Site

9/5/2014 06:03 am

(Wall Street Journal) Sept 4, 2014 - A hacker broke into part of the insurance enrollment website in July and uploaded malicious software, according to federal officials.

Gilead Close to Sending $84,000 Drug to Poor Countries

9/5/2014 06:03 am

(Bloomberg) Sept 4, 2014 - Gilead Sciences Inc. is close to a pact with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.